hydroxychloroquine has been researched along with Clinical Deterioration in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Clinical Deterioration: A critical disease progression, often measured by a set of clinical parameters, which activates HOSPITAL RAPID RESPONSE TEAM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China." | 1.56 | Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. ( Bhatt, PJ; Narayanan, N; Radbel, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Radbel, J | 1 |
| Narayanan, N | 1 |
| Bhatt, PJ | 1 |
| Dirim, AB | 1 |
| Demir, E | 1 |
| Ucar, AR | 1 |
| Garayeva, N | 1 |
| Safak, S | 1 |
| Oto, OA | 1 |
| Yazici, H | 1 |
| Alibeyoglu, AM | 1 |
| Orhun, G | 1 |
| Cagatay, AA | 1 |
| Turkmen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19[NCT04560205] | Phase 1 | 50 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for hydroxychloroquine and Clinical Deterioration
| Article | Year |
|---|---|
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azi | 2020 |
Fatal SARS-CoV-2 infection in a renal transplant recipient.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Deterioration; Coronavirus Infections; COV | 2020 |